Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation

BACKGROUND: Dabigatran is a novel oral anticoagulant approved for thromboprophylaxis in atrial fibrillation. Adoption patterns of this new agent in community practice are unknown. METHODS AND RESULTS: We studied patterns of dabigatran use among patients enrolled in the Outcomes Registry for Better I...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Steinberg, Benjamin A., Holmes, DaJuanicia N., Piccini, Jonathan P., Ansell, Jack, Chang, Paul, Fonarow, Gregg C., Gersh, Bernard, Mahaffey, Kenneth W., Kowey, Peter R., Ezekowitz, Michael D., Singer, Daniel E., Thomas, Laine, Peterson, Eric D., Hylek, Elaine M.
التنسيق: Artigo
اللغة:Inglês
منشور في: Blackwell Publishing Ltd 2013
الموضوعات:
Original Research
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC3886732/
https://ncbi.nlm.nih.gov/pubmed/24275632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.113.000535
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة